More Company News

Allergy Therapeutics

Phase I VLP Peanut PROTECT trial progress
26 Sep 2023Read More

Allergy Therapeutics

Satisfaction of FDI clearance conditions
22 Sep 2023Read More

Allergy Therapeutics

Trading update
10 Aug 2023Read More

Allergy Therapeutics

Appointment of CFO
10 Jul 2023Read More

Allergy Therapeutics

Interim H123 results and lifting of suspension in trading
19 Jun 2023Read More

Allergy Therapeutics

Publication of 2022 annual report and accounts
19 Jun 2023Read More

Allergy Therapeutics

Data at EAACI
09 Jun 2023Read More

Allergy Therapeutics

Skin-prick testing completes in PROTECT trial
19 Apr 2023Read More

Allergy Therapeutics

Statement regarding possible mandatory cash offer
06 Apr 2023Read More

Allergy Therapeutics

£40.75 million facility with equity financing
06 Apr 2023Read More

1 2 3 4 5
Return to Allergy Therapeutics
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).